4.185EUR-2.33%Mkt Cap: 874.45M EURP/E: —Last update: 2026-06-01
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in F…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap874.45M EUR
Enterprise Value1.02B EUR
Revenue (TTM)6.76M EUR
Gross Profit6.74M EUR
Net Income (TTM)-354.14M EUR
Revenue/Share0.0360 EUR
Last Price4.185 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees69
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0013233012
Valuation
P/E (Trailing)—
P/E (Forward)-5.53
PEG—
EV/EBITDA-7.71
EV/Revenue151.02
P/S132.43
P/B-28.95
EPS (TTM)-1.90
EPS (Forward)-0.77
52W Range
2.56045% of range6.200
52W High6.200 EUR
52W Low2.560 EUR
Profitability
Gross Margin99.68%
Oper. Margin-6710.69%
EBITDA Margin0.00%
Profit Margin-7899.58%
ROE1241.63%
ROA-141.93%
Growth
Revenue Growth-89.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-104.88M EUR
CapEx (TTM)247.00K EUR
FCF Margin-2968.67%
FCF Yield-22.95%
Net Debt131.05M EUR
Net Debt/EBITDA-0.99
Balance Sheet
Debt/Equity-2.10
Current Ratio3.16
Quick Ratio1.41
Book Value/Sh-0.1480 EUR
Cash/Share0.4810 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)10.09 EUR
Target Range7.000 EUR – 15.37 EUR
# Analysts5
Ownership
Shares Out.208.95M
Float135.14M
Insiders14.32%
Institutions60.98%
Technical
SMA 504.648 (-10.0%)
SMA 2004.475 (-6.5%)
Beta0.88
S&P 52W Chg27.94%
Avg Vol (30d)311.39K
Avg Vol (10d)270.93K
Technical Indicators
RSI (14)41.5
MACD-0.0535
MACD Signal-0.0464
MACD Hist.-0.0071
BB Upper4.982 EUR
BB Middle4.568 EUR
BB Lower4.154 EUR
BB Width18.12%
ATR (14)0.2817 EUR
Vol Ratio (20d)7.46x